KMT2A and leukemia: A recent study reported that MLL2 represents a more relevant therapeutic target in a range of MLL-rearranged leukemia models and that MLL2 and MLL1 collaborate to maintain oncogenesis via regulating distinctive gene-expression pathways (49).